Australia on Friday stopped the further development of a Covid-19 vaccine candidate as several participants in the early-stage trials generated antibodies for HIV after receiving the potential therapeutic.
There were no serious adverse events or safety concerns reported in the 216 participants of the phase 1 trial of the v451 COVID-19 vaccine candidate being developed by the University of Queensland (UQ) in collaboration with biotech company CSL, according to a statement.
However, data showed that some patients developed antibodies towards fragments of a HIV protein (gp41), which was used to stabilise the vaccine, it said.